{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:47:50Z","timestamp":1789789670182,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"DOI":"10.7759\/cureus.89944","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T04:32:23Z","timestamp":1755059543000},"source":"Crossref","is-referenced-by-count":3,"title":["The Use and Role of Mesalamine in the Treatment of Ulcerative Colitis: A Literature Review"],"prefix":"10.7759","author":[{"given":"Shalvin","family":"Chand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manvitha","family":"Bendagiri Matam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal K","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanathanan","family":"Neelakantan Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samyuktha","family":"Harikrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashasvi","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"The role of mesalamine in the treatment of ulcerative colitis","volume":"3","author":"Karagozian R","year":"2007","unstructured":"Karagozian R, Burakoff R. The role of mesalamine in the treatment of ulcerative colitis. Ther Clin Risk Manag. 2007, 3:893-903.","journal-title":"Ther Clin Risk Manag"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15876","article-title":"No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy","volume":"52","author":"Singh S","year":"2020","unstructured":"Singh S, Kim J, Zhu W, Dulai PS, Sandborn WJ, Jairath V. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther. 2020, 52:481-91. 10.1111\/apt.15876","journal-title":"Aliment Pharmacol Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39491-x","article-title":"5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis","volume":"13","author":"Wada H","year":"2023","unstructured":"Wada H, Miyoshi J, Kuronuma S, et al.. 5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis. Sci Rep. 2023, 13:12241. 10.1038\/s41598-023-39491-x","journal-title":"Sci Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cells8060523","article-title":"A phase 2a, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial of IBD98-M delayed-release capsules to induce remission in patients with active and mild to moderate ulcerative colitis","volume":"8","author":"Fiorino G","year":"2019","unstructured":"Fiorino G, Sturniolo GC, Bossa F, Cassinotti A, di Sabatino A, Giuffrida P, Danese S. A phase 2a, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial of IBD98-M delayed-release capsules to induce remission in patients with active and mild to moderate ulcerative colitis. Cells. 2019, 8:523. 10.3390\/cells8060523","journal-title":"Cells"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.12.036","article-title":"High dietary intake of specific fatty acids increases risk of flares in patients with ulcerative colitis in remission during treatment with aminosalicylates","volume":"15","author":"Barnes EL","year":"2017","unstructured":"Barnes EL, Nestor M, Onyewadume L, de Silva PS, Korzenik JR. High dietary intake of specific fatty acids increases risk of flares in patients with ulcerative colitis in remission during treatment with aminosalicylates. Clin Gastroenterol Hepatol. 2017, 15:1390-1396.e1. 10.1016\/j.cgh.2016.12.036","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.008","article-title":"AGA technical review on the management of mild-to-moderate ulcerative colitis","volume":"156","author":"Singh S","year":"2019","unstructured":"Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA technical review on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019, 156:769-808.e29. 10.1053\/j.gastro.2018.12.008","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13632","article-title":"Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders","volume":"174","author":"Curr\u00f2 D","year":"2017","unstructured":"Curr\u00f2 D, Ianiro G, Pecere S, Bibb\u00f2 S, Cammarota G. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol. 2017, 174:1426-49. 10.1111\/bph.13632","journal-title":"Br J Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae088","article-title":"Efficacy of dose escalation of oral 5-aminosalicylic acid for ulcerative colitis with a Mayo endoscopic subscore of 1: an open-label randomized controlled trial","volume":"31","author":"Fukuda T","year":"2025","unstructured":"Fukuda T, Aoki Y, Kiyohara H, et al.. Efficacy of dose escalation of oral 5-aminosalicylic acid for ulcerative colitis with a Mayo endoscopic subscore of 1: an open-label randomized controlled trial. Inflamm Bowel Dis. 2025, 31:716-24. 10.1093\/ibd\/izae088","journal-title":"Inflamm Bowel Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13120897","article-title":"Tackling the threat of cancer due to pathobionts producing colibactin: is mesalamine the magic bullet?","volume":"13","author":"Tang-Fichaux M","year":"2021","unstructured":"Tang-Fichaux M, Branchu P, Nougayr\u00e8de JP, Oswald E. Tackling the threat of cancer due to pathobionts producing colibactin: is mesalamine the magic bullet?. Toxins (Basel). 2021, 13:10.3390\/toxins13120897","journal-title":"Toxins (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2425","article-title":"Mesalamine-associated bradycardia","volume":"10","author":"Krzyzak M","year":"2018","unstructured":"Krzyzak M, Gupta A, Antonov E, Mulrooney SM. Mesalamine-associated bradycardia. Cureus. 2018, 10:e2425. 10.7759\/cureus.2425","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i15.2068","article-title":"Combination treatment of inflammatory bowel disease: present status and future perspectives","volume":"30","author":"Triantafillidis JK","year":"2024","unstructured":"Triantafillidis JK, Zografos CG, Konstadoulakis MM, Papalois AE. Combination treatment of inflammatory bowel disease: present status and future perspectives. World J Gastroenterol. 2024, 30:2068-80. 10.3748\/wjg.v30.i15.2068","journal-title":"World J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro R","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017, 389:1756-70. 10.1016\/S0140-6736(16)32126-2","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2020.0564","article-title":"Ulcerative colitis\u2014diagnostic and therapeutic algorithms","volume":"117","author":"Kucharzik T","year":"2020","unstructured":"Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative colitis\u2014diagnostic and therapeutic algorithms. Dtsch Arztebl Int. 2020, 117:564-74. 10.3238\/arztebl.2020.0564","journal-title":"Dtsch Arztebl Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/1756284821994741","article-title":"Can fecal calprotectin accurately identify histological activity of ulcerative colitis? A meta-analysis","volume":"14","author":"Ye X","year":"2021","unstructured":"Ye X, Wang Y, Wang HH, et al.. Can fecal calprotectin accurately identify histological activity of ulcerative colitis? A meta-analysis. Therap Adv Gastroenterol. 2021, 14:10.1177\/1756284821994741","journal-title":"Therap Adv Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2023.2279611","article-title":"Current and emerging biomarkers for ulcerative colitis","volume":"23","author":"Nowak JK","year":"2023","unstructured":"Nowak JK, Kalla R, Satsangi J. Current and emerging biomarkers for ulcerative colitis. Expert Rev Mol Diagn. 2023, 23:1107-19. 10.1080\/14737159.2023.2279611","journal-title":"Expert Rev Mol Diagn"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2020.08.025","article-title":"Calprotectin in inflammatory bowel disease","volume":"510","author":"Khaki-Khatibi F","year":"2020","unstructured":"Khaki-Khatibi F, Qujeq D, Kashifard M, Moein S, Maniati M, Vaghari-Tabari M. Calprotectin in inflammatory bowel disease. Clin Chim Acta. 2020, 510:556-65. 10.1016\/j.cca.2020.08.025","journal-title":"Clin Chim Acta"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/med.21893","article-title":"Inflammatory bowel disease biomarkers","volume":"42","author":"Liu D","year":"2022","unstructured":"Liu D, Saikam V, Skrada KA, Merlin D, Iyer SS. Inflammatory bowel disease biomarkers. Med Res Rev. 2022, 42:1856-87. 10.1002\/med.21893","journal-title":"Med Res Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2023-325668","article-title":"Inflammatory bowel disease: recent developments","volume":"109","author":"Ashton JJ","year":"2024","unstructured":"Ashton JJ, Beattie RM. Inflammatory bowel disease: recent developments. Arch Dis Child. 2024, 109:370-6. 10.1136\/archdischild-2023-325668","journal-title":"Arch Dis Child"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0676-z","article-title":"Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of ulcerative colitis","volume":"58","author":"Berends SE","year":"2019","unstructured":"Berends SE, Strik AS, L\u00f6wenberg M, D'Haens GR, Math\u00f4t RA. Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of ulcerative colitis. Clin Pharmacokinet. 2019, 58:15-37. 10.1007\/s40262-018-0676-z","journal-title":"Clin Pharmacokinet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/03602532.2024.2303507","article-title":"The aminosalicylate - folate connection","volume":"56","author":"London RE","year":"2024","unstructured":"London RE. The aminosalicylate - folate connection. Drug Metab Rev. 2024, 56:80-96. 10.1080\/03602532.2024.2303507","journal-title":"Drug Metab Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s13105-024-01033-y","article-title":"Modulation of miR-155-5p signalling via 5-ASA for the prevention of high microsatellite instability: an in vitro study using human epithelial cell lines","volume":"80","author":"Adamowicz M","year":"2024","unstructured":"Adamowicz M, Abramczyk J, Kilanczyk E, Milkiewicz P, \u0141aba A, Milkiewicz M, Kempinska-Podhorodecka A. Modulation of miR-155-5p signalling via 5-ASA for the prevention of high microsatellite instability: an in vitro study using human epithelial cell lines. J Physiol Biochem. 2024, 80:573-83. 10.1007\/s13105-024-01033-y","journal-title":"J Physiol Biochem"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.998470","article-title":"Identification and exploration of pharmacological pyroptosis-related biomarkers of ulcerative colitis","volume":"13","author":"Chen K","year":"2022","unstructured":"Chen K, Shang S, Yu S, Cui L, Li S, He N. Identification and exploration of pharmacological pyroptosis-related biomarkers of ulcerative colitis. Front Immunol. 2022, 13:998470. 10.3389\/fimmu.2022.998470","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05058-1","article-title":"Predictive biomarkers for anti-TNF alpha therapy in IBD patients","volume":"22","author":"Kumar M","year":"2024","unstructured":"Kumar M, Murugesan S, Ibrahim N, Elawad M, Al Khodor S. Predictive biomarkers for anti-TNF alpha therapy in IBD patients. J Transl Med. 2024, 22:284. 10.1186\/s12967-024-05058-1","journal-title":"J Transl Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.107778","article-title":"Biomarkers prediction and immune landscape in ulcerative colitis: findings based on bioinformatics and machine learning","volume":"168","author":"Yang Y","year":"2024","unstructured":"Yang Y, Hua Y, Zheng H, et al.. Biomarkers prediction and immune landscape in ulcerative colitis: findings based on bioinformatics and machine learning. Comput Biol Med. 2024, 168:107778. 10.1016\/j.compbiomed.2023.107778","journal-title":"Comput Biol Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-024-00633-9","article-title":"Lower fecal microbiota transplantation ameliorates ulcerative colitis by eliminating oral-derived Fusobacterium nucleatum and virulence factor","volume":"16","author":"Li DH","year":"2024","unstructured":"Li DH, Li ZW, Sun Q, Wang L, Ning SB. Lower fecal microbiota transplantation ameliorates ulcerative colitis by eliminating oral-derived Fusobacterium nucleatum and virulence factor. Gut Pathog. 2024, 16:42. 10.1186\/s13099-024-00633-9","journal-title":"Gut Pathog"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.989654","article-title":"The efficacy of mesalazine on nonspecific terminal ileal ulcers: a randomized controlled trial","volume":"13","author":"Li J","year":"2022","unstructured":"Li J, Ling F, Guo D, et al.. The efficacy of mesalazine on nonspecific terminal ileal ulcers: a randomized controlled trial. Front Pharmacol. 2022, 13:989654. 10.3389\/fphar.2022.989654","journal-title":"Front Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-019-1049-2","article-title":"The culprit of mesalamine intolerance: case series and literature review","volume":"19","author":"Xie C","year":"2019","unstructured":"Xie C, Quan R, Hong F, Zou K, Yan W, Fu Y. The culprit of mesalamine intolerance: case series and literature review. BMC Gastroenterol. 2019, 19:138. 10.1186\/s12876-019-1049-2","journal-title":"BMC Gastroenterol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-02938-6","article-title":"Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis","volume":"23","author":"Chu X","year":"2023","unstructured":"Chu X, Biao Y, Liu C, et al.. Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis. BMC Gastroenterol. 2023, 23:346. 10.1186\/s12876-023-02938-6","journal-title":"BMC Gastroenterol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005573.pub3","article-title":"Probiotics for induction of remission in ulcerative colitis","volume":"3","author":"Kaur L","year":"2020","unstructured":"Kaur L, Gordon M, Baines PA, Iheozor-Ejiofor Z, Sinopoulou V, Akobeng AK. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020, 3:CD005573. 10.1002\/14651858.CD005573.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.78208","article-title":"Mesalazine-induced myocarditis in inflammatory bowel disease: a systematic review","volume":"17","author":"Jhakri K","year":"2025","unstructured":"Jhakri K, Al-Shudifat M, Sumra B, Kocherry C, Shamim H, Mohammed L. Mesalazine-induced myocarditis in inflammatory bowel disease: a systematic review. Cureus. 2025, 17:e78208. 10.7759\/cureus.78208","journal-title":"Cureus"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab010","article-title":"Efficacy of oral, topical, or combined oral and topical 5-aminosalicylates in ulcerative colitis: systematic review and network meta-analysis","volume":"15","author":"Barberio B","year":"2021","unstructured":"Barberio B, Segal JP, Quraishi MN, Black CJ, Savarino EV, Ford AC. Efficacy of oral, topical, or combined oral and topical 5-aminosalicylates in ulcerative colitis: systematic review and network meta-analysis. J Crohns Colitis. 2021, 15:1184-96. 10.1093\/ecco-jcc\/jjab010","journal-title":"J Crohns Colitis"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011572.pub2","article-title":"Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis","volume":"9","author":"Jairath V","year":"2017","unstructured":"Jairath V, Zou GY, Parker CE, et al.. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev. 2017, 9:CD011572. 10.1002\/14651858.CD011572.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12216929","article-title":"Treatment of patients with mild to moderate ulcerative colitis: a Middle East expert consensus","volume":"12","author":"Awadhi SA","year":"2023","unstructured":"Awadhi SA, Alboraie M, Albaba EA, et al.. Treatment of patients with mild to moderate ulcerative colitis: a Middle East expert consensus. J Clin Med. 2023, 12:6929. 10.3390\/jcm12216929","journal-title":"J Clin Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092510","article-title":"Drug optimization in patients with mild-to-moderate ulcerative colitis: a global survey","volume":"13","author":"D'Amico F","year":"2024","unstructured":"D'Amico F, Jairath V, Paridaens K, Peyrin-Biroulet L, Danese S. Drug optimization in patients with mild-to-moderate ulcerative colitis: a global survey. J Clin Med. 2024, 13:2510. 10.3390\/jcm13092510","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/393475-the-use-and-role-of-mesalamine-in-the-treatment-of-ulcerative-colitis-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T04:32:24Z","timestamp":1755059544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/393475-the-use-and-role-of-mesalamine-in-the-treatment-of-ulcerative-colitis-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.89944","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}